share_log

Exscientia Says EXS4318 Drug Candidate Has Entered Phase 1 Clinical Trials in US -- Shares Rise

Exscientia、EXS4318の新薬候補が米国で第1相臨床試験に入ったと発表--株価が上昇

MT Newswires ·  2023/02/02 11:16

Unity Software(U.US) reported fourth-quarter financial results after the market close on Monday. Here's a rundown of the report.Q4 Earnings: Unity said fourth-quarter revenue increased 35% year-over-year to $609 million, beating the consensus estimate of $562.71 million. The company reported a quarterly loss of 66 cents per share.

これらの内容は、情報提供及び投資家教育のためのものであり、いかなる個別株や投資方法を推奨するものではありません。 更に詳しい情報
    コメントする